Please login to the form below

Not currently logged in
Email:
Password:

PI ARM names Mike Burman as senior director

He has experience working with Bristol-Myers Squibb and AstraZeneca

PI ARM, part of ProPharma Group, has appointed Mike Burman as senior director.

In the role, Burman will provide leadership in strategic planning, key client relationships and delivering excellence to the medical information company's global client base.

Commenting on the appointment, Kirk Hoffman, PI ARM vice president, said: “We are excited about the experience Mike is bringing to the company.

“His understanding of both the client and service side of the pharmaceutical industry, coupled with his extensive international experience will be very helpful to us as we continue to expand our global business. We are very pleased to have Mike join our leadership team.”

Burman has previously included the design and implementation of the global medical information contact centre at Bristol-Myers Squibb and the virtual scientific exchange centre at AstraZeneca.

He has held a number of medical information management positions and is additionally active in several professional organisations and is a frequent speaker at various industry conferences.

PI ARM provides global, medical information solutions to pharma, biotech and medical device companies.

13th January 2015

From: Marketing

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

The ALS patient journey
Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...
Equipping your medical affairs teams with solutions to navigate the healthcare landscape
Dr Tyler Ray, OPEN Health Medical Communications...
Protein degraders
Can protein degraders unlock ‘undruggable’ drug targets?
Exploring a new and exciting area of small-molecule drug discovery...

Infographics